Track topics on Twitter Track topics that are important to you
LONDON, Aug. 8, 2017 /PRNewswire/ -- Oppenheimer Europe Ltd. ("Oppenheimer"), a subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), announced today that it is establishing a Healthcare corporate finance franchise as the Firm continues to expand its investment banking capabilities in EMEA. The Firm has appointed Christian Luding as Managing Director and European Head of Healthcare Investment Banking.
The franchise will further strengthen Oppenheimer's global Healthcare Corporate Finance capabilities. Oppenheimer has a well-established Healthcare investment banking business in the U.S., supported by dedicated equity research covering over 100 publicly-listed healthcare companies. By making a substantial investment to set up an experienced team in Europe, Oppenheimer can serve both its U.S. and European clients with a fully-dedicated and deeply specialized global Healthcare M&A and advisory practice.
The team will be led by Mr. Luding, who joins Oppenheimer with over 15 years of investment banking experience at UBS, Lazard, and Nomura– in both London and New York – advising healthcare clients on mergers, acquisitions, divestitures, and debt and equity financings. Mr. Luding holds a Bachelor's degree from Emory University and an MBA from the NYU Stern School of Business.
Max Lami, Chief Executive Officer of Oppenheimer Europe said, "We are delighted that Christian has decided to join our Firm. As a highly respected and experienced practitioner, Christian and the team will immeasurably strengthen our Healthcare presence in the EMEA markets. We are very proud of our success in building a business based on deep, long-term relationships with our clients on both sides of the Atlantic."
Robert Lowenthal, Head of US Investment Banking at Oppenheimer & Co. Inc., commented, "As our clients' interests have increasingly shifted to Europe with cross-border transactions, we continue to add bankers in Europe to supplement our U.S. capabilities. The combination of our strong ECM and equity research platforms and senior bankers with world class domain expertise enables us to act as trusted advisors to our European clients in the healthcare sector."
Mr. Luding said, "I am thrilled to have the opportunity to build a first class M&A and capital-raising advisory business offering our European clients a superior advisory service based on global reach, excellence in execution of transactions, and deep-domain expertise across all healthcare verticals."
Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.
About Oppenheimer Europe
Oppenheimer Europe Ltd. is a subsidiary of Oppenheimer Holdings (NYSE:OPY), Inc. With over 3,400 employees and more than 90 offices around the world, Oppenheimer is a global full-service investment bank focusing on growth sectors and premier mid-market companies. At Oppenheimer Europe, the integrated team of sector and product specialists provides financial services to European based institutions and corporations across Corporate Finance, Equities, Fixed Income, Debt Capital Markets and Portfolio Strategy Research. For more information about Oppenheimer, please visit www.opco.com.
SOURCE Oppenheimer Europe Ltd.NEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...